| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Assessment of Needs for Plasma for Fractionation in Europe
|
Burckhardt, Johann J.
|
|
1999
|
27 |
4 |
p. 337-341
5 p.
|
artikel
|
| 2 |
Assessment of Validation Studies from a Fractionator's Point of View
|
Zerlauth, Gerold
|
|
1999
|
27 |
4 |
p. 295-301
7 p.
|
artikel
|
| 3 |
Contents and Index to Vol. 27
|
|
|
1999
|
27 |
4 |
p. i-xii
nvt p.
|
artikel
|
| 4 |
Editorial
|
Müller-Breitkreutz, Konstanze
|
|
1999
|
27 |
4 |
p. 279-
1 p.
|
artikel
|
| 5 |
European Multi-Centre Validation Study of NucliSens Extractor in Combination with HCV Amplicor 2·0 Assay for HCV-NAT Screening of Plasma Pools
|
Cuypers, H.T.M.
|
|
1999
|
27 |
4 |
p. 303-314
12 p.
|
artikel
|
| 6 |
Experiences in HCV-NAT Screening Prior to Releasing Cellular Components by the German Red Cross Blood Transfusion Service of Baden-Württemberg
|
Cardoso, M.S.
|
|
1999
|
27 |
4 |
p. 281-284
4 p.
|
artikel
|
| 7 |
NAT: Perspectives for Cellular Components
|
Barbara, John A.J.
|
|
1999
|
27 |
4 |
p. 333-336
4 p.
|
artikel
|
| 8 |
Performance Characteristics of the AmpliScreenTMHIV-1 Test, an Assay designed for Screening Plasma Mini-pools
|
Yang, Yanfeng
|
|
1999
|
27 |
4 |
p. 315-323
9 p.
|
artikel
|
| 9 |
Risk–Benefit Analysis of Nucleic Acid Testing: The French Experience
|
Saura, C.
|
|
1999
|
27 |
4 |
p. 343-348
6 p.
|
artikel
|
| 10 |
Safety Issues for Plasma Derivatives and Benefit from NAT Testing
|
Willkommen, Hannelore
|
|
1999
|
27 |
4 |
p. 325-331
7 p.
|
artikel
|
| 11 |
Sixth EPFA/NIBSC Workshop on NAT in Rome 1999: Outcome of Discussions†
|
Müller-Breitkreutz, Konstanze
|
|
1999
|
27 |
4 |
p. 349-352
4 p.
|
artikel
|
| 12 |
Standardization: a Progress Report
|
Saldanha, John
|
|
1999
|
27 |
4 |
p. 285-289
5 p.
|
artikel
|
| 13 |
Validation of HCV-NAT Assays and Experience with NAT Application for Blood Screening in Germany
|
Nübling, C.Micha
|
|
1999
|
27 |
4 |
p. 291-294
4 p.
|
artikel
|
Tijdschrift beschrijving